

## \$1.4 million raised through completion of Share Purchase Plan (SPP)

MELBOURNE, 16 November 2020: Anatara Lifesciences (ASX: ANR) is pleased to advise that the Share Purchase Plan (SPP) announced to the market on 21 October 2020 closed on 11 November 2020 oversubscribed.

The SPP was open to eligible shareholders from Australia, New Zealand and the United Kingdom. Valid applications totalling \$2,069,500 were received.

Given the strong support shown by eligible shareholders, Anatara has decided to increase the SPP size above its original target of \$750,000 to \$1.4 million.

Due to the strong level of applications in the SPP, it is necessary for Anatara to scale back those applications. The scale back will be conducted on a pro-rata basis taking into account the number of Shares held as at 7.00pm (Melbourne time) on 20 October 2020 (Record Date).

The issue price of the SPP Shares will be 80% of the VWAP of the ordinary shares in Anatara calculated over the last 5 days on which sales in ordinary shares were recorded before 18 November 2020 on which the issue of the SPP Shares will be made (Issue Date), subject to a floor price of \$0.15 per SPP Share in the event the 80% VWAP is less than \$0.15.

SPP Shares are expected to be quoted on the ASX on Thursday 19 November 2020. Anatara recommends shareholders confirm their actual holding prior to trading in SPP shares.

Authorised for release by the Board of Anatara Lifesciences Ltd

Subscribe to Anatara Investor Relations Updates:

<https://anataralifesciences.com/contact/email-alerts/>

**For more information please contact:**

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

## About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

### Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email [info@anatara.com](mailto:info@anatara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)

